Xeris Biopharma Holdings Azioni (NASDAQ: XERS)

Ultime notizie per Xeris Biopharma Holdings (NASDAQ:XERS) Azioni

XERIS BIOPHARMA HOLDINGS INC

Xeris Biopharma Holdings

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings Inc

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4400524-1&amp;h=3599259149&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaCODMDTm04NfEnDJWV6qSIGHOjnChncC-RpLjY6rcsbMXPbLxqxBNyXLnOYxxNzMP8MAAVGmI0pUPtnq579KmwETCXHiWXJRroZibpsxr50%3D&amp;a=FatPipe%2C+Inc.%C2%A0">FatPipe, Inc.&nbsp;</a>("FatPipe" or the "Company"), a pioneer in enterprise-class, application-aware, secure software-defined wide area network ("SD-WAN") solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and middle-market companies, is pleased to announce the pricing of its underwritten initial public offering of 695,656 shares of common stock at a public offering price of $5.75 per share. The shares of common stock have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on April 8, 2025, under the ticker symbol "FATN."
The Company expects to receive aggregate gross proceeds of $4 million from the offering, before deducting underwriting discounts and other related expenses.&nbsp;In addition, the Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 104,348 shares of common stock at the public offering price, less underwriting discounts. The closing for the initial public offering is expected to occur on or about April 9, 2025, subject to satisfaction of customary closing conditions.
D. Boral Capital LLC is acting as the Sole Book-Running Manager for the offering.

News

IPOs

FATN

FatPipe Prices $4M IPO Of 695,656 Shares Of Common Stock At A Price Of $5.75 Per Share

- Brazil's Petrobras CEO Tells Reuters

Brazil's Petrobras CEO Says May Not Change Prices For Fuels While Scenario Remains Turbulent; Will Not Bring International Scenario Jitters To The Domestic Market

<a href="https://www.ibm.com/new/announcements/Meta-llama-4-maverick-and-llama-4-scout-now-available-in-watsonx-ai" title="https://www.ibm.com/new/announcements/Meta-llama-4-maverick-and-llama-4-scout-now-available-in-watsonx-ai">https://www.ibm.com/new/announcements/Meta-llama-4-maverick-and-llama-4-scout-now-available-in-watsonx-ai</a>

'Meta Llama 4 Maverick And Llama 4 Scout Now Available In watsonx.ai'

NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 27.03 percent increase over losses of $(0.74) per share from the same period last year.

Earnings

Earnings Beats

NRSN

NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate

Bausch Health Companies 13D Filing Shows Alex Meruelo Reported A 9.99% Stake In The Co As Of March 31, 2025; Expressed Willingness To Join Board Of Bausch Health Companies & Help Co Identify Other Strategic Individuals To Join Board

Bluejay Diagnostics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting offering fees and other expenses payable by the Company.
In consideration for the exercise of the Existing Warrants for cash, the investors received new warrants (the "New Warrants") to purchase up to an aggregate of 1,085,106 shares of common stock. The New Warrants are exercisable immediately at an exercise price of $3.42 per common share and will expire five years from the issuance date.

Offerings

BJDX

Bluejay Diagnostics Secures $3.7M In Gross Proceeds Through Agreement With Institutional Investors To Exercise 1,085,106 Existing Warrants At $3.42 per Share

FCNCA

First Citizens BancShares Says FCB Determined That Likelihood Of Reaching $5B Loss Threshold In 5-Year Period Of Shared-Loss Agreement Was Remote

PRFX

PainReform FY24 EPS $(32.16) Up From $(63.13) YoY

<a href="https://variety.com/2025/biz/news/skydance-paramount-merger-extension-fcc-approval-1236362262/" title="https://variety.com/2025/biz/news/skydance-paramount-merger-extension-fcc-approval-1236362262/">https://variety.com/2025/biz/news/skydance-paramount-merger-extension-fcc-approval-1236362262/</a>

PARA

'Skydance-Paramount Merger Agreement, Which Is Still Pending FCC Approval, Extended for 90 Days' - Variety

On April 7, 2025, First-Citizens Bank &amp; Trust Company ("FCB"), a North Carolina chartered commercial bank and direct, wholly owned subsidiary of First Citizens BancShares, Inc. ("BancShares"), entered into a Termination Agreement (the "Termination Agreement") with the Federal Deposit Insurance Corporation (the "FDIC") to provide for the early termination of the commercial shared-loss agreement (the "Shared-Loss Agreement") executed by and between FCB and the FDIC in connection with FCB's acquisition of certain assets and assumption of certain liabilities of Silicon Valley Bridge Bank, N.A. in an FDIC-assisted transaction (the "SVBB Acquisition") on March 27, 2023 (the "SVBB Acquisition Date").
 &nbsp;
The Shared-Loss Agreement covered an estimated $60 billion of loans (collectively, the "covered assets") at the SVBB Acquisition Date. Under the terms of the Shared-Loss Agreement, the FDIC agreed to reimburse FCB for 0% of losses of up to $5 billion with respect to covered assets and 50% of losses in excess of $5 billion with respect to covered assets ("FDIC loss sharing"), and FCB agreed to reimburse the FDIC for 50% of recoveries related to such covered assets ("FCB reimbursement"). The Shared-Loss Agreement provided for FDIC loss sharing for five years and FCB reimbursement for eight years. As a result of entering into the Termination Agreement, all rights and obligations of the parties under the Shared-Loss Agreement terminated as of the effective date of the Termination Agreement (the "Termination Date"), including FCB's reporting covenants and obligations related to FDIC loss sharing and FCB reimbursement. As of the Termination Date, no payments or other obligations are due or outstanding by FCB or the FDIC under the Shared-Loss Agreement. The Termination Agreement includes transition provisions for the benefit of FCB's related debt agreements with the FDIC, all of which survive termination of the Shared-Loss Agreement, including the purchase money note payable by FCB (the "Purchase Money Note"), which had an outstanding principal amount of $35.99 billion as of December 31, 2024, and bears interest at a fixed rate of 3.50% per annum until its maturity in March 2028.
 &nbsp;
The decision to terminate the Shared-Loss Agreement was motivated, in part, by FCB's determination that the likelihood of reaching the $5 billion loss threshold during the five-year period covered by the Shared Loss Agreement was remote. Additionally, the Termination Agreement will eliminate the reporting responsibilities associated with the Shared-Loss Agreement.

Contracts

Legal

First-Citizens Bank & Trust Company Reaches Termination Agreement With FDIC To End Shared-Loss Agreement Related To Silicon Valley Bridge Bank Acquisition, Eliminating Future Loss Sharing And Reporting Obligations

- SEC Filing
&nbsp;
Our operating partnership, Digital Realty Trust, L.P., issued and sold $1,150,000,000 aggregate principal amount of its 1.875% exchangeable senior notes due 2029, or the notes, in a private transaction that closed in November 2024. The notes are fully and unconditionally guaranteed by us. Under certain circumstances, we may issue shares of our common stock, $0.01 par value per share, or our common stock, upon the exchange of the notes. In such circumstances, the recipients of such shares of common stock, whom we refer to herein as the selling securityholders, may use this prospectus to resell from time to time such shares. Additional selling securityholders may be named by future prospectus supplements.
The registration of the shares of our common stock covered by this prospectus does not necessarily mean that any of the selling securityholders will exchange their notes for our common stock, that upon any exchange of the notes we will elect, in our sole and absolute discretion, to exchange some or all of the notes for shares of our common stock rather than cash, or that any shares of our common stock received upon exchange of the notes will be offered or sold by the selling securityholders.

Digital Realty Trust Files Prospectus For Offering Of Upto 6.7M Common Stock

<h3>Gainers</h3>
<ul>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) stock rose 13.9% to $7.2 during Monday's after-market session. The market value of their outstanding shares is at $92.0 million. </li>
<li>El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) shares rose 10.41% to $10.25. The market value of their outstanding shares is at $305.1 million. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock increased by 7.37% to $0.71. The market value of their outstanding shares is at $6.1 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares moved upwards by 7.13% to $0.36. The company's market cap stands at $12.3 million. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) stock moved upwards by 5.76% to $0.55. The market value of their outstanding shares is at $10.2 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGB#NASDAQ">QVCGB</a>) stock moved upwards by 5.12% to $5.95. The market value of their outstanding shares is at $2.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock fell 9.7% to $0.35 during Monday's after-market session. The market value of their outstanding shares is at $100.8 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares declined by 6.69% to $0.3. The market value of their outstanding shares is at $13.7 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) shares fell 5.95% to $1.9. The company's market cap stands at $2.8 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares decreased by 5.81% to $0.13. The company's market cap stands at $6.5 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock decreased by 4.94% to $0.49. The market value of their outstanding shares is at $3.8 million. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock fell 4.65% to $2.65. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

GDHG

LOBO

LOCO

MKDW

NWTN

PLCE

QVCGB

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock moved upwards by 17.2% to $4.98 during Monday's after-market session. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock moved upwards by 14.64% to $292.0. The market value of their outstanding shares is at $35.2 billion. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) stock rose 13.7% to $0.9. The company's market cap stands at $31.9 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) stock moved upwards by 13.48% to $26.0. The market value of their outstanding shares is at $1.2 billion. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock moved upwards by 9.76% to $0.19. The company's market cap stands at $8.9 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares moved upwards by 9.19% to $0.19. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock fell 19.2% to $1.05 during Monday's after-market session. The market value of their outstanding shares is at $50.3 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock fell 14.22% to $9.9. The market value of their outstanding shares is at $257.7 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 13.92% to $0.42. The company's market cap stands at $2.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock decreased by 13.68% to $4.61. The market value of their outstanding shares is at $29.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares declined by 11.78% to $0.32. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 10.14% to $6.74. The market value of their outstanding shares is at $3.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVRX

DHAI

ENTO

FBRX

OGEN

PCRX

RNXT

STTK

TNFA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares rose 37.3% to $1.29 during Monday's after-market session. The company's market cap stands at $23.2 million. </li>
<li>Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares moved upwards by 29.81% to $9.71. The company's market cap stands at $296.9 million. </li>
<li>Conduent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) shares rose 9.85% to $2.66. The market value of their outstanding shares is at $430.2 million. </li>
<li>Copa Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) shares rose 8.16% to $90.0. The company's market cap stands at $3.7 billion. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) stock moved upwards by 6.11% to $0.63. The market value of their outstanding shares is at $18.3 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock increased by 6.03% to $11.25. The company's market cap stands at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) shares fell 11.3% to $3.21 during Monday's after-market session. The market value of their outstanding shares is at $749.3 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) stock decreased by 7.33% to $1.88. The company's market cap stands at $1.3 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock fell 7.16% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) stock decreased by 7.08% to $1.05. The company's market cap stands at $36.3 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock declined by 6.67% to $1.26. The company's market cap stands at $2.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock declined by 5.63% to $0.23. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CNDT

CNTM

CTOS

CVGI

GLXG

ICON

IPDN

SGBX

SPIR

WLGS

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares increased by 69.8% to $5.5 during Monday's after-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) stock moved upwards by 13.21% to $5.91. The market value of their outstanding shares is at $10.4 million. </li>
<li>Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) shares moved upwards by 6.42% to $1.49. The company's market cap stands at $73.1 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock moved upwards by 5.57% to $1.48. The company's market cap stands at $29.6 million. </li>
<li>Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) shares rose 5.41% to $16.15. The market value of their outstanding shares is at $860.6 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) stock moved upwards by 5.33% to $11.85. The market value of their outstanding shares is at $77.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) shares decreased by 8.9% to $0.76 during Monday's after-market session. The company's market cap stands at $45.6 million. </li>
<li>Lianhe Sowell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) stock decreased by 8.51% to $3.02. The market value of their outstanding shares is at $156.9 million. </li>
<li>QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) shares decreased by 6.52% to $4.45. The company's market cap stands at $70.3 million. </li>
<li>Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) shares decreased by 6.42% to $3.5. The company's market cap stands at $104.5 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) stock fell 5.94% to $0.74. The market value of their outstanding shares is at $27.3 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares fell 5.01% to $0.44. The market value of their outstanding shares is at $4.6 million. As per the press release, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCS

CMCM

LHSW

MOBX

NTRP

Penguin Solutions, Inc. - Ordinary Shares

PENG

QMCO

QUIK

SLNH

SVRE

WRAP

12 Information Technology Stocks Moving In Monday's After-Market Session

WIIM

Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.

In the preceding three months, 5 analysts have released ratings for Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $72.8, a high estimate of $80.00, and a low estimate of $68.00. This current average has increased by 3.26% from the previous average price target of $70.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744059669_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Brookfield's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mario Saric &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $68.00&#x7C;$71.00 &#x7C; 
&#x7C;Cherilyn Radbourne &#x7C;TD Securities &#x7C;Raises &#x7C;Buy &#x7C; $75.00&#x7C;$74.00 &#x7C; 
&#x7C;Mario Saric &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $71.00&#x7C;$69.00 &#x7C; 
&#x7C;Michael Cyprys &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $80.00&#x7C;- &#x7C; 
&#x7C;Dean Wilkinson &#x7C;CIBC &#x7C;Raises &#x7C;Outperformer &#x7C; $70.00&#x7C;$68.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Brookfield. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Brookfield compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Brookfield's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Brookfield's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Brookfield analyst ratings.</a>
<h2>Unveiling the Story Behind Brookfield</h2>
Brookfield Corp is an investment firm focused on building long-term wealth for institutions and individuals. It has three businesses Asset Management, Wealth Solutions, Renewable Power and Transition, Infrastructure, Private Equity, Real Estate and Corporate Activities. it invests in real assets that form the backbone of the economy to deliver risk-adjusted returns to stakeholders. It generates the majority of its revenue from Asset Management. It has a geographic presence in the UK, the United States, Australia, Canada, Brazil, India, Colombia, Germany, Other Europe, Other Asia, and other countries.
<h3>Unraveling the Financial Story of Brookfield</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3M period, Brookfield faced challenges, resulting in a decline of approximately -20.77% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Brookfield's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Brookfield's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.93%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Brookfield's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.08%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Brookfield's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.61, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Brookfield: Insights From 5 Financial Analysts

Analysts' ratings for Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.0, a high estimate of $32.00, and a low estimate of $20.00. A 1.06% drop is evident in the current average compared to the previous average price target of $27.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744059659_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Blue Owl Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$29.00 &#x7C; 
&#x7C;Michael Brown &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $22.00&#x7C;$24.00 &#x7C; 
&#x7C;Benjamin Budish &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $29.00&#x7C;- &#x7C; 
&#x7C;Brian McKenna &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $32.00&#x7C;$32.00 &#x7C; 
&#x7C;Brian McKenna &#x7C;JMP Securities &#x7C;Raises &#x7C;Market Outperform&#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Christopher Allen &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $30.00&#x7C;- &#x7C; 
&#x7C;Glenn Schorr &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $26.00&#x7C;$25.00 &#x7C; 
&#x7C;Bill Katz &#x7C;TD Cowen &#x7C;Raises &#x7C;Buy &#x7C; $28.00&#x7C;$26.00 &#x7C; 
&#x7C;Michael Brown &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $24.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blue Owl Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blue Owl Capital compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Blue Owl Capital's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Blue Owl Capital's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OWL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blue Owl Capital analyst ratings.</a>
<h2>About Blue Owl Capital</h2>
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
<h3>A Deep Dive into Blue Owl Capital's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Blue Owl Capital displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 27.8%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Blue Owl Capital's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blue Owl Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Blue Owl Capital's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.19%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 1.4, Blue Owl Capital faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Blue Owl Capital Through The Eyes Of 9 Analysts

Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Avery Dennison, revealing an average target of $208.17, a high estimate of $225.00, and a low estimate of $189.00. Experiencing a 8.16% decline, the current average is now lower than the previous average price target of $226.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1744059650_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Avery Dennison's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $189.00&#x7C;$207.00 &#x7C; 
&#x7C;Scott Gaffner &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $225.00&#x7C;$245.00 &#x7C; 
&#x7C;Matt Roberts &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $208.00&#x7C;$218.00 &#x7C; 
&#x7C;Michael Roxland &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $215.00&#x7C;$245.00 &#x7C; 
&#x7C;Jeffrey Zekauskas &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $205.00&#x7C;$210.00 &#x7C; 
&#x7C;Joshua Spector &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $207.00&#x7C;$235.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avery Dennison. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Avery Dennison compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Avery Dennison's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Avery Dennison's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AVY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avery Dennison analyst ratings.</a>
<h2>Get to Know Avery Dennison Better</h2>
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
<h3>Avery Dennison's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Avery Dennison showcased positive performance, achieving a revenue growth rate of 3.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Avery Dennison's net margin excels beyond industry benchmarks, reaching 7.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Avery Dennison's ROE stands out, surpassing industry averages. With an impressive ROE of 7.39%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Avery Dennison's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.36, Avery Dennison adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Avery Dennison Stock: Analyst Perspectives (6 Ratings)

16 analysts have expressed a variety of opinions on Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $94.06, a high estimate of $125.00, and a low estimate of $57.00. This current average has decreased by 14.9% from the previous average price target of $110.53. 
<img src="https://www.benzinga.com/files/images/story/2025/1744059644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Five Below among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Announces &#x7C;Neutral &#x7C; $57.00&#x7C;- &#x7C; 
&#x7C;Michael Montani &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $90.00&#x7C;$93.00 &#x7C; 
&#x7C;Kate McShane &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $102.00&#x7C;$117.00 &#x7C; 
&#x7C;John Heinbockel &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $125.00&#x7C;$140.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $85.00&#x7C;$85.00 &#x7C; 
&#x7C;David Bellinger &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $88.00&#x7C;$105.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $110.00&#x7C;$150.00 &#x7C; 
&#x7C;Karen Short &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $93.00&#x7C;$100.00 &#x7C; 
&#x7C;Scot Ciccarelli &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $86.00&#x7C;$93.00 &#x7C; 
&#x7C;Melanie Nunez &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $75.00&#x7C;$88.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $110.00&#x7C;$120.00 &#x7C; 
&#x7C;Anthony Chukumba &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $75.00&#x7C;$120.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $85.00&#x7C;$115.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $102.00&#x7C;$107.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $115.00&#x7C;$115.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $107.00&#x7C;$110.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Five Below. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Five Below compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Five Below's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Five Below's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Five Below analyst ratings.</a>
<h2>All You Need to Know About Five Below</h2>
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
<h3>Five Below's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Five Below displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 3.97%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Five Below's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Five Below's ROA excels beyond industry benchmarks, reaching 4.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Five Below's debt-to-equity ratio is below the industry average. With a ratio of 1.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FIVE

Expert Outlook: Five Below Through The Eyes Of 16 Analysts

Press Releases

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Xeris to Participate in Upcoming Investor Conferences

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Comments

Xeris Biopharma Holdings

Notizie

Ultime notizie per Xeris Biopharma Holdings (NASDAQ:XERS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO